https://www.pharmaradar360.com/article/bf89575e8b0fcba9PharmaRadar360en2026-04-25T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/fb92135dd2fae2f1PharmaRadar360en2026-04-25T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/0c97bd6335a40a25PharmaRadar360en2026-04-25T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/2ba7d9182741429aPharmaRadar360en2026-04-25T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/2775c35e71228d9dPharmaRadar360en2026-04-25T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/45a89b82b4e627f8PharmaRadar360en2026-04-25T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/dc8ba82ac757c1c0PharmaRadar360en2026-04-25T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/845e58cb84bec8d8PharmaRadar360en2026-04-25T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/0ad253270ae93d68PharmaRadar360en2026-04-25T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/5c5ae6fa0c84edffPharmaRadar360en2026-04-25T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/7eb1c8f8943760b2PharmaRadar360en2026-04-25T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/cdbc5fc2917399bePharmaRadar360en2026-04-25T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/29138a4780cfeb37PharmaRadar360en2026-04-25T00:00:00.000Z6203https://www.pharmaradar360.com/article/229f85355446d093PharmaRadar360en2026-04-25T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/8da3013fbc220862PharmaRadar360en2026-04-24T20:21:36.000ZSuspensión de Servicioshttps://www.pharmaradar360.com/article/b6747d2d2792653aPharmaRadar360en2026-04-24T18:27:25.000ZANMAT facilita la importación de productos necesarios para el desarrollo de estudios clínicoshttps://www.pharmaradar360.com/article/3655a327bf552f29PharmaRadar360en2026-04-24T18:01:45.000ZBehind the Budget: What Sites Really Need to Know Todayhttps://www.pharmaradar360.com/article/1858133b71545cfbPharmaRadar360en2026-04-24T17:32:04.000ZWhy Site Support Goes Unused in Clinical Trialshttps://www.pharmaradar360.com/article/f6854e926bdf73daPharmaRadar360en2026-04-24T17:27:36.000ZMobility in Clinical Trial Operations with the SIP Mobile App: Practical Gains, New Friction Points, and What to Watchhttps://www.pharmaradar360.com/article/c83ceed34322ab63PharmaRadar360en2026-04-24T17:22:23.000ZCardiometabolic Trials are Exposing a Flaw in the Clinical Research Model: Retention is Engineered Upstreamhttps://www.pharmaradar360.com/article/8f4ca351670454d4PharmaRadar360en2026-04-24T17:20:15.000ZBridging Innovation and Reality: Why Human Support Is Essential in Tech-Enabled Clinical Trialshttps://www.pharmaradar360.com/article/462f78ba45101b0dPharmaRadar360en2026-04-24T14:22:20.000ZClass 3 Medicines Recall: Omega Pharma Ltd, Napralief 250mg Gastro-Resistant Tablets, EL(26)A/21https://www.pharmaradar360.com/article/8e580c6c2b578e3bPharmaRadar360en2026-04-24T14:00:00.000Z日本新薬アドバンス主催「ふれあいまつり」を開催https://www.pharmaradar360.com/article/6f9d4aea34bfc8eaPharmaRadar360en2026-04-24T10:59:00.000ZBristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Companyhttps://www.pharmaradar360.com/article/e0868bb2850eb6d3PharmaRadar360en2026-04-24T10:45:00.000ZMerck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.https://www.pharmaradar360.com/article/841a2e9c8108e318PharmaRadar360en2026-04-24T08:31:55.000ZΓενόσημα Ιανουάριος 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/7cf510772f73d5acPharmaRadar360en2026-04-24T08:00:02.000Z2026年12月期第1四半期連結決算https://www.pharmaradar360.com/article/ca6ec36aa0b9f92fPharmaRadar360en2026-04-24T08:00:02.000ZChugai Announces 2026 1st Quarter Resultshttps://www.pharmaradar360.com/article/3b41249912881c48PharmaRadar360en2026-04-24T08:00:01.000Z組織改正・人事のお知らせhttps://www.pharmaradar360.com/article/5d825f99afb09dc1PharmaRadar360en2026-04-24T08:00:01.000ZOrganizational and Personnel Changeshttps://www.pharmaradar360.com/article/c59781c9635c1d2dPharmaRadar360en2026-04-24T08:00:00.000Z信託型株式報酬制度の導入に伴う株式取得の詳細決定に関するお知らせhttps://www.pharmaradar360.com/article/6e67eab1f9e43afcPharmaRadar360en2026-04-24T08:00:00.000ZDetermination of Details Regarding Share Acquisition Associated with the Introduction of the Trust-Based Stock Compensation Systemhttps://www.pharmaradar360.com/article/d97fac3de6ecbee2PharmaRadar360en2026-04-24T07:22:20.000ZLa AEMPS informa de un posible error de software en las versiones 1.5 a 1.6 de la aplicación Dexcom One+ iOShttps://www.pharmaradar360.com/article/eb511d98a7d90e7dPharmaRadar360en2026-04-24T06:40:47.000ZΕπικοινωνία σχετικά με την οριστική διακοπή κυκλοφορίας επιλεγμένων σκευασμάτων ινσουλίνηςhttps://www.pharmaradar360.com/article/fd38d2ac6de1f230PharmaRadar360en2026-04-24T02:30:00.000ZAstellas Amends Settlement and License Agreement with MSN regarding Myrbetriq®https://www.pharmaradar360.com/article/8596a28edc606f85PharmaRadar360en2026-04-24T00:00:00.000ZShop — Petro's Chili & Chips™https://www.pharmaradar360.com/article/48372b94c06d39c3PharmaRadar360en2026-04-24T00:00:00.000ZWhy You Should Drink Water After You Wake Uphttps://www.pharmaradar360.com/article/4c190fccec795c5aPharmaRadar360en2026-04-23T20:05:00.000ZAbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.https://www.pharmaradar360.com/article/e6a3f18787b0b11ePharmaRadar360en2026-04-23T16:00:00.000ZA free gene therapy? Regeneron’s Otarmeni approved for hearing losshttps://www.pharmaradar360.com/article/084d259909a55cb8PharmaRadar360en2026-04-23T16:00:00.000ZFDA, CMS partner to deliver RAPIDly for innovative devices